Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.631
Buy
RSI(14)
57.784
Neutral
STOCH(KDJ)(9,3,3)
69.592
Sell
ATR(14)
7.003
High Vlolatility
CCI(14)
50.616
Neutral
Williams %R
30.304
Buy
TRIX(12,20)
0.351
Sell
StochRSI(14)
0.000
Sell
Search
Jazz Pharmaceuticals PLC
JAZZAdd to Watchlist
252.860USD
-5.520-2.14%
Close 07-31 16:00（ET）Quotes delayed by 15 min
15.53BMarket Cap
613.23P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-2.14%
5 Days
-0.40%
1 Month
+4.93%
6 Months
+53.72%
Year to Date
+48.74%
1 Year
+120.59%
Key Figures
258.090Open
259.060High
572.98KVolume
613.23P/E TTM
8.90P/E Dynamic
--Dividend TTM
0.93%Turnover Ratio
258.380Prev. Close
250.710Low
106.46MTurnover
27.73P/E Static
3.60P/B
0.00%Div Yield TTM
0.23%ROA
243.32052wk High
0.79Volume Ratio
560.12MNet Profit
61.44MShares
0.4123EPS TTM
0.32Beta
0.63%ROE
105.00052wk Low
3.23%Amplitude
71.34%Gross Margin
15.53BMarket Cap
3.48Reward/Risk
1.76%Risk Rate
TradingKey Stock Score of Jazz Pharmaceuticals PLC
Currency: USD Updated: 2026-07-31Key Insights
Jazz Pharmaceuticals PLC's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 13 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 269.20.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Jazz Pharmaceuticals PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Jazz Pharmaceuticals PLC Highlights
StrengthsRisks
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Overvalued
The company’s latest PE is 613.23, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 70.31M shares, decreasing 1.06% quarter-over-quarter.
Held by Tweedy Browne
Star Investor Tweedy Browne holds 47.90K shares of this stock.
Analyst Rating
Based on
20
analysts
Buy
Current Rating
269.204
Target Price
+5.17%
Upside Space
Jazz Pharmaceuticals PLC News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
20
analysts
Buy
Current Rating
269.204
Target Price
+5.17%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Jazz Pharmaceuticals PLC
JAZZ
20
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
255.912
Sell
MA10
253.640
Sell
MA20
248.566
Buy
MA50
239.466
Buy
MA100
219.720
Buy
MA200
191.363
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Jazz Pharmaceuticals PLC Info
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Ticker SymbolJAZZ
CompanyJazz Pharmaceuticals PLC
CEOGala (Renee D)
Websitehttps://www.jazzpharma.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-0.92%
-2.51%
+0.32%
-1.45%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
+1.30%
-0.90%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Jazz Pharmaceuticals PLC (JAZZ)?
The current price of Jazz Pharmaceuticals PLC (JAZZ) is 252.73.
What is the symbol of Jazz Pharmaceuticals PLC?
The ticker symbol of Jazz Pharmaceuticals PLC is JAZZ.
What is the 52-week high of Jazz Pharmaceuticals PLC?
The 52-week high of Jazz Pharmaceuticals PLC is 243.32.
What is the 52-week low of Jazz Pharmaceuticals PLC?
The 52-week low of Jazz Pharmaceuticals PLC is 105.00.
What is the market capitalization of Jazz Pharmaceuticals PLC?
The market capitalization of Jazz Pharmaceuticals PLC is 15.53B.
Is Jazz Pharmaceuticals PLC (JAZZ) currently rated as Buy, Hold, or Sell?
According to analysts, Jazz Pharmaceuticals PLC (JAZZ) has an overall rating of Buy, with a price target of 269.20.
What is the Earnings Per Share (EPS TTM) of Jazz Pharmaceuticals PLC (JAZZ)?
The Earnings Per Share (EPS TTM) of Jazz Pharmaceuticals PLC (JAZZ) is -5.84.